Shares of Eli Lilly (LLY) jumped 16% Thursday morning to lead 澳洲幸运5开奖号码历史查询:S&P 500 gainers after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines."

The first of seven 澳洲幸运5开奖号码历史查询:Phase 3 trials for orforglipron showed it was more effective than a placebo at causing weight loss and a reduction in A1C, a long-term blood sugar metric used in evaluating diabetes treatments, Lilly said. The red🌸uctions in weight and A1C increased 💜for patients taking higher doses of the drug.

The drug had similar gastrointestinal side effects to Eli Lilly's injectible weight-loss drugs Mounjaro and Zepbound, including nausea, indigestion, and diarrhea. The rate of patients reporting the side effects also varied among different doses, impacting 10% to 26% of patients.

Eli Lilly said it plans to present the data at a conference and in a peer-reviewed journal. Results from other trials for orforglipron will be released later this year, and the company expects to file for 澳洲幸运5开奖号码历史查询:Food and Drug Administration (FDA) approval as a type 2 diabetes treat🐽ment in 2026.

Lilly, rival Novo Nordisk (NVO), and others are in development of new weight-loss treatments that can be taken orally rather than injected. Pfizer (PFE) 澳洲幸运5开奖号码历史查询:halted an oral drug trial earlier this wee𓆉k after a patient reported a liver injury.

While Eli Lilly shares soared on the news, those of Novo Nordisk—the maker of blockbuster drugs 澳洲幸运5开奖号码历史查询:Ozempic and Wegovy—sank 7% soon after the opening bell.

UPDATE—This article has been updated with the latest share price information